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Purpose of the study
In the CASTLE study, lower response rates were observed
in patients with baseline HIV-RNA ≥100,000 copies/mL
in both arms and were associated with lower baseline
CD4 cell count for LPV/r but not ATV/r.
Methods
Randomized, open-label, prospective study comparing
once-daily ATV/r with twice-daily LPV/r, both with fixed-
dose TDF/FTC in 883 treatment-naive patients. Treatment
outcomes of HIV-RNA <50 c/mL at week 48 using con-
firmed virologic response (CVR) and grade 2–4 treatment-
related AEs through week 48 are presented by pre-speci-
fied baseline HIV-RNA and CD4 cell count strata.
Summary of results
The proportion of responders (CVR HIV-RNA <50 c/mL,
ITT) at week 48 by baseline HIV RNA strata (<100,000,
100,000–<500,000, and ≥500,000) were 83%, 76%, and
64% for ATV/r and 80%, 74%, and 61% for LPV/r (Table
1).
In patients with both baseline CD4 <100 and HIV-RNA
≥100,000, 60/83 (72%) on ATV/r and 40/64 (63%) on
LPV/r achieved HIV RNA <50 c/mL (CVR, ITT). Incidence
of grades 2–4 treatment-related AEs through week 48 by
baseline HIV-RNA strata (<100,000, 100,000–<500,000,
and ≥500,000) were 29%, 26%, and 15% for ATV/r; and
31%, 27%, and 30% for LPV/r. (Table 2.)
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Table 1: CVR Treatment Outcomes of HIV RNA <50 c/mL at Week 48 by Baseline CD4 Cell Count, n (%).
ATV/r LPV/r
As-Randomized <50 50–<100 100–<200 ≥200 <50 50–<100 100–<200 ≥200
ITT n = 58 n = 45 n = 106 n = 222 n = 48 n = 29 n = 134 n = 228
Responder 45 (78) 34 (76) 80 (75) 178 (80) 30 (63) 20 (69) 104 (78) 182 (80)
Virologic failure* 7 (12) 7 (16) 17 (16) 26 (12) 6 (13) 7 (24) 13 (10) 24 (11)
Discontinued 6 (10) 4 (9) 9 (8) 16 (7) 12 (25) 2 (7) 16 (12) 20 (9)
On-treatment, n/N (%) 45/52 (87) 34/40 (85) 80/95 (84) 178/202 (88) 30/35 (86) 20/25 (80) 104/114 (91) 182/201 (91)
*Includes never suppressed and on study through week 48, discontinued due to insufficient viral load response through week 48, and rebound 
without resuppression.Page 1 of 2
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Lower response rates at higher baseline HIV-RNA were
seen for both ATV/r and LPV/r. The trend for lower
response rates at lower baseline CD4 cell counts for LPV/
r observed in the ITT analysis did not appear to be present
in the on-treatment analysis. ATV/r and LPV/r had consist-
ent adverse event (AE) profiles within each arm by base-
line HIV-RNA. More AEs, most commonly diarrhea and
nausea, were observed with LPV/r at low baseline CD4 cell
counts.
Table 2: Grade 2–4 Treatment-Related AEs through Week 48 by Baseline CD4 Cell Count (cells/mm3), n (%).
ATV/r LPV/r
As-treated <50 50–<100 100–<200 ≥200 <50 50–<100 100–<200 ≥200
n = 59 n = 45 n = 106 n = 222 n = 47 n = 29 n = 133 n = 224
Any 12 (20) 9 (20) 22 (21) 71 (32) 19 (40) 7 (24) 35 (26) 65 (29)
Jaundice 1 (2) 0 2 (2) 12 (5) 0 0 0 0
Diarrhea 0 1 (2) 3 (3) 6 (3) 8 (17) 3 (10) 12 (9) 26 (12)
Nausea 2 (3) 0 6 (6) 9 (4) 5 (11) 2 (7) 9 (7) 16 (7)Page 2 of 2
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